Sign in
Taking people in United StatesPhase 2

Removing certain immune cells from stem cell transplants for blood cancers

Tests a stem cell transplant with some immune cells removed, in blood cancer patients.

Key facts

Who runs it
University of Florida
Where
Gainesville, United StatesSee the site
Trial code
Registry title
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
Status
Recruiting
Phase
Phase 2
People taking part
20 people, planned
Started
3 May 2024
Expected to end
May 2028
Type of study
Interventional
Treatments tested
  • Miltenyi CliniMACS Prodigy ® system
Record updated
4 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children, teens and young adults with certain blood cancers or lymphoma who need a stem cell transplant from a donor.

Age
6 months to 39 years
Sex
All sexes can join.
Disease stage
ALL, AML, JMML, CML, high risk MDS, Hodgkin or Non-Hodgkin lymphoma. Disease must be high risk, relapsed, in later remission, or not cleared by earlier treatment.
Earlier treatment
A donor stem cell transplant within the last 6 months cannot have been given, unless it is a boost.
Biomarker or test result
Some groups need specific findings: for example t(9;22) or 11q23 change, FLT3 change, or JMML without CBL mutation. A sibling, unrelated or half-matched family donor must be available.

Main reasons for not taking part

  • Infection that is not under control
  • Active graft-versus-host disease of Grade 2 or higher
  • Pregnant or breastfeeding
  • Not using contraception during the trial and for 8 weeks after the last dose
  • In prison or held by order for treatment

The registry criteria, word for word

Show all 41 criteriaShow less

Who can take part

  • Children, Adolescents, Young adults (ages 6 months to ≤39 years) with the following diseases may be eligible:
  • ALL
  • ALL high risk including one or more of the following: (t(9;22) or 11q23 chromosomal abnormality, primary induction failure (≤15% blasts at time of registration), mixed phenotype acute leukemia (MPAL), persistent MRD (≥0.01% by flow or persistent abnormal karyotype detected by cytogenetics) or hypodiploidy (≤44 chromosomes)) in first remission
  • ALL in second remission and beyond
  • AML
  • History of AML induction/reinduction Failure (≤15% blasts at time of registration)
  • AML in CR1 with poor cytogenetics (i.e., 12p, 5a, -7, FLT3 mutation/duplication, t(9;11) and others)
  • AML with persistent minimal residual disease (MRD) in CR1(≥0.01% on flow or persistent abnormal karyotype detected by cytogenetics)
  • AML CR2 or beyond
  • AML in refractory relapse but ≤15% bone marrow leukemia blasts
  • Therapy-related AML
  • Juvenile MyeloMonocytic Leukemia (JMML)
  • JMML in CR1 without CBL mutation
  • JMML with recurrence of disease with or without CBL mutation
  • JMML CR2 or beyond
  • Chronic Myeloid Leukemia (CML)
  • CML in CR with regard to blast crisis
  • High Risk Myelodysplastic syndrome (MDS)
  • Lymphoma: Hodgkin (HL) or Non-Hodgkin (NHL)
  • HL or NHL with a history of induction failure
  • HL or NHL in PR1 or PR2
  • HL or NHL in CR2 or subsequent remission
  • Subjects must not have more than one active malignancy at the time of enrollment (Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen [as determined by the treating physician and approved by the PI] may be included)
  • HLA-matched (5-6/6) sibling donor, matched (8-10/10) unrelated donor available for stem cell donation, haplo-identical related donor (at least one full haplotype must be matched)
  • Karnofsky or Lansky score ≥60% at the time of enrollment. Karnofsky scores must be used for patients >16 years of age and Lansky scores for patients ≤16 years of age
  • Adequate organ function (within 4 weeks of initiation of preparative regimen), defined as:
  • Pulmonary: FEV1, FVC, and corrected DLCO must all be ≥ 60% of predicted by pulmonary function tests (PFTs). For children who are unable to perform for PFTs due to age, the criteria are: no evidence of dyspnea at rest and no need for supplemental oxygen
  • Renal: Creatinine clearance or radioisotope GFR ≥60 mL/min/1.73 m2 or a serum creatinine based on age/gender
  • Cardiac: Shortening fraction of ≥ 27% by echocardiogram) or ejection fraction of ≥ 50% by echocardiogram or radionuclide scan (MUGA)
  • Hepatic: SGOT (AST) or SGPT (ALT) < 5 x upper limit of normal (ULN) for age. Conjugated bilirubin < 2.5 mg/dL, unless attributable to Gilbert's Syndrome
  • Written informed consent obtained from the subject or guardian and the subject agrees to comply with all the study-related procedures
  • Subjects of childbearing potential (SOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for at least 8 weeks after the last dose of study drug to minimize the risk of pregnancy
  • Subjects with partners of child-bearing potential must agree to use physician-approved contraceptive methods (e.g., abstinence, condoms, vasectomy) throughout the study and should avoid conceiving children for 8 weeks following the last dose of study drug

Who cannot take part

  • Patients who have received allogeneic hematopoietic stem cell transplantation within 6 months, unless being done as a boost
  • Females or males of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 8 weeks after the last dose of study drug
  • Patients with documented uncontrolled infection
  • Prisoners or subjects who are incarcerated, or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness
  • History of any other disease, metabolic dysfunction, clinical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician
  • Patients with active ≥Grade 2 aGVHD
  • Demonstrated lack of compliance with medical care
  • Females who are known to be pregnant or breastfeeding

Where in United States

  • University of FloridaGainesville, United StatesContact: Beate GreerTaking people

About the trial

What the trial wants to find out

This study will assess the safety, efficacy, and feasibility of ⍺/β CD3+ T-cell and CD19+ B-cell depletion in allogeneic stem cell transplantation in patients with acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), juvenile myelomonocytic leukemia (JMML), high risk myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML) and lymphoma. Subjects will receive an allogeneic stem cell transplant that has been depleted of ⍺/β CD3+ T-cells and CD19+ B-cells using the Miltenyi CliniMACS Prodigy® system.

The group in the trial

  • Allogeneic stem cell transplant with ⍺/β CD3+ T-cell and CD19+ B-cell depleted graftTreatment being tested

    Treatment: Miltenyi CliniMACS Prodigy ® system

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
Plain-language title
Removing certain immune cells from stem cell transplants for blood cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
4 June 2026